Defensin Peptides vs Retinol: Two Approaches to Visible Skin Renewal
Both defensin peptides and retinol are used to visibly address skin aging — but they work through fundamentally different biological pathways, with different tolerability profiles. More importantly, they are not competitors: used together, they may address aspects of visible skin aging that neither reaches alone.
Retinoids are a family of vitamin A derivatives that range from gentle over-the-counter cosmeceuticals to potent prescription-only drugs. All retinoids ultimately work by converting to retinoic acid in the skin — but the conversion steps differ, and so does the potency and tolerability profile. Understanding where each retinoid sits on this spectrum helps clarify where defensins fit alongside them.
All four retinoids work through pathways in existing basal skin cells. Defensin peptides are associated in published research with a different cell population — LGR6+ stem cells — which sit above the hair follicle bulge and are involved in skin renewal during wound healing.
Both retinol and defensins are used for visible anti-aging. So what actually separates them biologically?
Retinol — in all its forms from OTC to prescription tretinoin — works through pathways in existing basal skin cells. Retinoids bind to nuclear receptors (RAR and RXR) that influence gene expression, supporting accelerated visible turnover of existing keratinocytes and collagen-related changes in existing fibroblasts. The cells retinol acts on are the same basal stem cells that have been accumulating UV damage, oxidative stress, and epigenetic alterations throughout a patient's lifetime. Retinol supports those cells to work harder and turn over faster. That is genuinely useful and well-documented across decades of clinical research.
Defensin peptides are associated in published research with a different pathway. Alpha-Defensin 5 and Beta-Defensin 3 are patented, fully synthetic, bioidentical innate immune molecules. In peer-reviewed research, they have been associated with LGR6+ stem cell activity — a dormant reserve that remains largely quiescent during life, residing in the hair follicle isthmus where it accumulates comparatively less UV exposure and damage than proliferating basal cells. Published research documents that topical application of these defensin peptides was associated with visible improvements in skin quality across multiple measures, without the inflammation or photosensitivity associated with retinoids. Taub & Pham (Facial Plast Surg Clin N Am, 2018) describe this distinction: retinol acts on existing basal stem cells, while defensin peptides are associated with LGR6+ stem cell activity — cells that have accumulated comparatively less damage.
Both pathways have a legitimate place in a well-designed skincare approach. Many patients and providers use both. The distinction is which cells are involved and what tolerability trade-offs apply — not which ingredient is categorically superior.
For a deeper look at how defensins compare to a specific retinol-based system used in medical practices, see Defensin Peptides vs ZO Skin Health® Retinol Systems.
Retinol and defensins are complementary, not competing. Retinol supports accelerated visible turnover of existing skin cells. Defensins are associated in published research with a different renewal-related pathway. In the Taub et al. 2018 multi-center, double-blind, vehicle-controlled trial (PMID: 29601620), participants using defensin-based regimens demonstrated visible improvement across 22 measures of skin quality. The published conclusion notes the full formula achieved results consistent with those of retinol-based approaches, "without the irritation, dryness, or inflammation associated with retinols."
For patients whose skin does not tolerate retinoids, defensins offer an evidence-based option associated with visible improvement through a different pathway. For patients who already use retinoids, defensins may address complementary aspects of visible skin renewal.
Two patented, lab-synthesized bioidentical peptides — Alpha-Defensin 5 and Beta-Defensin 3. Fully synthetic, vegan, no human-, animal-, or marine-derived material. Associated in peer-reviewed research with LGR6+ stem cell-related skin renewal pathways. Not associated with inflammation or increased photosensitivity in published study participants. Five published peer-reviewed clinical studies. Exclusive to DefenAge. Can be used by patients who do not tolerate retinoids, and alongside retinoids for patients who do.
Vitamin A derivatives — retinyl esters, retinol, retinaldehyde (OTC), and tretinoin (prescription). All convert to retinoic acid in the skin and work through RAR/RXR nuclear receptors in existing skin cells, supporting visible cell turnover and collagen-related changes. Decades of published clinical evidence for visible improvement. Associated with a tolerability spectrum from mild (retinyl esters) to significant (tretinoin): retinoid dermatitis, photosensitivity, and barrier disruption are documented tolerability considerations. Not associated with LGR6+ stem cell pathways in published research.
The Published Clinical Evidence — Study by Study
Understanding the published evidence base for defensin technology in the context of visible skin improvement.
Multi-center, double-blind, vehicle-controlled trial
Participants using the DefenAge defensin regimen demonstrated statistically significant visible improvement across 22 measures of skin quality. Histopathology showed increased epidermal thickness with no signs of inflammation in published histological analysis and no significant increase in cell proliferation markers. The published conclusion states the full formula achieved results "without the irritation, dryness, or inflammation associated with retinols" and offers "most of the advantages of time-honored retinols…without irritation or inflammation, sun-sensitivity, or concerns about neoplasia."
JDD 2018;17(4):426–441. PMID: 29601620
Periocular wrinkles — PRO formula independent trial
Independent follow-up trial using enhanced-concentration defensin formula. Statistically significant visible improvement in periocular fine lines and wrinkles, including elastosis. Improvements noted across wrinkles, laxity, dyschromia, erythema, texture, and radiance. Good product tolerability confirmed in study participants.
JDD 2023;22(9):874–880. PMID: 37683059
Six-week pilot — visible skin quality improvement
22 subjects applied a DefenAge defensin regimen for 6 weeks. At week 6, subjects' skin quality scores advanced from near-average to the 78th percentile versus a matched reference population — a change described as a visible reduction in apparent skin age of approximately 18 years as measured by the "evenness" parameter. 100% of subjects noted visible improvement in their own assessment. This pilot led directly to the Taub et al. 2018 multi-center trial.
Keller G. Advanced Aesthetics & Cosmetic Dermatology Symposium, 2014. Cited in Taub et al. JDD 2018.
Systematic review — visible antiaging effects of topical defensins
Systematic review of defensin clinical evidence across face, periocular, and body sites. Documented visible improvements in skin elasticity, moisture content, TEWL, pigmentation, pores, and wrinkles. Explicitly noted that future studies should compare defensins to retinoids "which may be characterized by side effects such as retinoid dermatitis" — acknowledging both the tolerability distinction and the need for direct comparative research.
Facial Plast Surg Clin N Am. 2023;31:535–546. doi: 10.1016/j.fsc.2023.05.010
Microneedling with defensins — post-procedure protocol evidence
In a split-face pilot study, participants treated with microneedling plus defensin-based serum demonstrated greater visible improvement than participants treated with microneedling plus PRP. Quantitative wrinkle reduction index: defensin side 501 vs PRP side 389 in a representative case. Defensins were applied 30 minutes post-procedure — a timing principle relevant to post-procedure and combination protocol design.
Facial Plast Surg Clin N Am. 2018;26(4):447–454. PMID: 30213426
Retinoid clinical evidence: The retinoid literature is among the most extensive in cosmetic dermatology. Multiple randomized, double-blind, vehicle-controlled studies demonstrate that retinol (0.25–1.0%), retinaldehyde (0.05–0.1%), and prescription tretinoin are associated with statistically significant visible improvements in fine lines, wrinkles, pigmentation, elasticity, and overall photodamage. The evidence base for retinoids is deep and well-established. The published distinction is that they work through pathways in existing cells, while defensin peptides have been associated in research with a different renewal-related pathway involving comparatively less-damaged LGR6+ stem cell populations.
How Do Defensin Peptides Differ from Retinol?
The fundamental published distinction between defensin peptides and retinol is the cell population each is associated with. Retinol works through pathways in existing basal stem cells. Defensin peptides have been associated in peer-reviewed research with LGR6+ stem cell-related activity — cells that are largely quiescent during life and have accumulated comparatively less UV damage. This distinction is documented in published literature (Taub & Pham, Facial Plast Surg Clin N Am, 2018) and explains why the two may be used together: they are associated with different pathways that do not appear to overlap.
Two Layers of Visible Skin Renewal
The rationale for using both: retinol supports the visible turnover of existing skin cells. Defensins are associated in published research with a different renewal-related pathway involving the LGR6+ stem cell reserve — cells that have accumulated comparatively less damage during life. Retinol supports the existing pipeline. Defensins are associated with a different, complementary source of visible renewal.
DefenAge's published materials confirm that defensins are compatible with retinoids and note: "defensins can be combined with ANY skincare — including retinol." This reflects the published observation that defensin peptides and retinoids are associated with different, non-overlapping cell populations. There is no known biological overlap or interference between these pathways based on current published understanding.
Defensins are also compared to other advanced technologies used in medical aesthetics, including growth factor-based systems such as SkinMedica TNS® and exosome-based skincare — each representing a different approach to visible skin renewal.
Using Defensins Alongside Prescription Tretinoin
For patients using prescription tretinoin, the order of application may influence skin comfort. The following layering approach — based on DefenAge's professional channel guidance — is designed to help support skin tolerance while maintaining each product's intended role.
This layering approach is based on DefenAge's professional protocol guidance and is intended for use under the supervision of a licensed healthcare provider who has prescribed tretinoin. Individual responses vary significantly — consult your prescribing provider before making changes to any prescription regimen. This does not constitute medical advice.
Key Differences at a Glance
| Category | DefenAge® Age-Repair Defensins® | Retinol / Retinoids (OTC & Rx) |
|---|---|---|
| Associated cell pathway | Associated in published research with LGR6+ stem cell-related renewal activity — a comparatively less-damaged, quiescent cell reserve involved in wound-related skin renewal. | Works through pathways in existing basal stem cells — the proliferating cell population that has been accumulating UV damage and epigenetic changes throughout life. |
| Visible mechanism | Associated in published research with visible skin quality improvements through a renewal-related pathway distinct from retinoid mechanisms. | Supports accelerated visible cell turnover. Binds RAR/RXR nuclear receptors in existing keratinocytes and fibroblasts to influence gene expression related to visible skin renewal. |
| Tolerability in studies | Well tolerated in published study participants. Not associated with inflammation or barrier disruption in published histological analysis (Taub et al. 2018). | Associated with a tolerability spectrum. Retinoid dermatitis — redness, peeling, barrier disruption — is a documented tolerability consideration, particularly with prescription tretinoin and higher retinol concentrations. |
| Photosensitivity | Not associated with increased UV sensitivity in published studies. Can be used morning and evening without additional UV precautions beyond standard daily SPF. | Associated with increased photosensitivity. Generally recommended for nighttime use, with daytime SPF essential. |
| Sensitive skin suitability | Well tolerated in published study participants including those with sensitive skin. Associated with barrier support rather than barrier disruption. | Tolerability varies. OTC retinoids generally better tolerated than prescription tretinoin — but retinoid sensitivity varies widely among patients. |
| Published product studies | 5 peer-reviewed studies across 4 journals — face serum, eye cream, body cream, periocular RCT, microneedling comparison. Histopathology and ultrasound evaluation included. | Decades of published randomized controlled trials. Among the most extensively studied ingredients in cosmetic dermatology. Evidence for visible improvement is robust and well-established. |
| Prescription required | No prescription required. Available through professional practices and defenage.com. | OTC retinoids available without prescription. Tretinoin — the most potent and most studied form — requires a prescription. |
| Compatibility | Compatible with all retinoid forms. Associated with different, non-overlapping pathways. No known biological interference based on current published understanding. | Compatible with defensins. Retinoids are associated with different pathways that do not appear to overlap with defensin-related activity. |
| Vegan / synthetic | Fully synthetic. No human-, animal-, or marine-derived material. | Generally synthetic. Most OTC and prescription retinoid products are vegan-compatible, though formulation vehicles vary. |
Four Reasons Defensins Address What Retinol Cannot Reach
Different cell pathways — published distinction
Retinol works through pathways in existing basal stem cells that have been accumulating photodamage throughout life. Defensin peptides have been associated in peer-reviewed literature with LGR6+ stem cell-related renewal activity — a comparatively less-damaged, quiescent cell population. This distinction is published (Taub & Pham, 2018) and explains why the two may be used together: they address different aspects of visible skin renewal through different pathways.
For patients who do not tolerate retinoids
Retinoid dermatitis affects a significant proportion of patients and is particularly common with prescription tretinoin. Many discontinue retinoid therapy due to tolerability concerns. The Danielian et al. 2023 systematic review noted that future research should directly compare defensins to retinoids given this tolerability distinction. In the Taub et al. 2018 trial, histopathological analysis showed no signs of inflammation and no significant increase in cell proliferation markers — a tolerability profile documented to differ from retinol's known mechanism.
No photosensitivity — no timing restrictions
Retinoids are associated with increased UV sensitivity and are generally recommended for nighttime use only with daytime SPF essential. Defensin peptides are not associated with increased photosensitivity in published studies and can be used morning and evening without additional UV precautions. For patients building a morning-focused visible anti-aging routine, defensins are the evidence-based option with no photosensitivity constraint.
A published rationale for using both
Retinol and defensins are associated with different, non-overlapping pathways in published research. Retinol supports visible turnover of existing cells. Defensins are associated with a different renewal-related pathway. The published rationale for using both: two layers of visible skin renewal, addressing complementary pathways that neither ingredient reaches alone. DefenAge explicitly confirms compatibility with retinoids in its published materials.
Which Approach Is Right for Your Patient?
DefenAge may be right for your patient if:
- Their skin does not tolerate retinoids — even low-concentration OTC retinol is associated with redness, peeling, or barrier disruption in their experience
- They are already using retinol or tretinoin and want to address a complementary visible renewal pathway that retinoids are not associated with
- They want a visible anti-aging option that can be used morning and evening without photosensitivity considerations
- They have sensitive skin, rosacea, or a compromised barrier that is not well suited to retinoid-associated tolerability effects
- They are motivated by peer-reviewed published evidence — specifically the five-study evidence base including multi-center, double-blind histopathology-confirmed trial data
- They want a professionally dispensed, fully synthetic, vegan option with no human-, animal-, or marine-derived ingredients
Retinoids remain the right choice when:
- The patient tolerates retinoids well and values the most extensively published topical visible anti-aging ingredient in dermatology
- The goal is specifically to address active acne, significant photodamage, or melasma — indications where the retinoid evidence base is particularly deep
- The patient's primary visible concern is cell turnover acceleration and the texture improvement associated with retinoid-driven visible exfoliation
- The ideal outcome is using both retinoids and defensins together — addressing visible turnover through retinol while also supporting the complementary defensin-associated renewal pathway
Retinol is one of the most well-evidenced ingredients in cosmetic dermatology. Its association with visible improvement in fine lines, wrinkles, pigmentation, and photodamage is documented across decades of published research. This comparison is not about which ingredient is superior — it is about which pathways each one is associated with and what that means for different patients.
Retinol works through pathways in existing basal skin cells that have been cycling throughout life, accumulating photodamage and epigenetic changes. Defensin peptides have been associated in published peer-reviewed research with a different renewal-related pathway — LGR6+ stem cell activity — involving a comparatively less-damaged, quiescent cell population. The Taub et al. 2018 published conclusion puts it directly: the defensin full formula offers results consistent with retinol-based approaches "without the irritation, dryness, or inflammation associated with retinols."
For patients who do not tolerate retinoids, defensins offer a published evidence-based option associated with visible improvement through a different pathway. For patients who already use retinoids, defensins may address complementary aspects of visible skin renewal. The most complete approach for many patients is both: two layers of visible renewal, working through pathways that do not overlap.
References & Further Reading
- Taub A, Bucay V, Keller G, Williams J, Mehregan D. "Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen." Journal of Drugs in Dermatology. 2018;17(4):426–441. PMID: 29601620
- Hartman N, Loyal J, Taub A, Fabi S. "Clinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles." Journal of Drugs in Dermatology. 2023;22(9):874–880. doi: 10.36849/JDD.7184. PMID: 37683059
- Berens AM, Ghazizadeh S. "Effect of defensins-containing eye cream on periocular rhytids and skin quality." Journal of Cosmetic Dermatology. 2020;19(8):2000–2005. PMID: 32614135
- Eggerstedt M, Torres-Maldonado S, Danielian A, Hwang SHJ, Echanique KA. "Impact of defensins-containing body cream on skin composition." Journal of Cosmetic Dermatology. 2023;22(2):620–627. PMID: 35621235
- Duncan DI. "Microneedling with Biologicals: Advantages and Limitations." Facial Plastic Surgery Clinics of North America. 2018;26(4):447–454. PMID: 30213426
- Danielian A, Danielian M, Cheng MY, et al. "Antiaging Effects of Topical Defensins." Facial Plastic Surgery Clinics of North America. 2023;31:535–546. doi: 10.1016/j.fsc.2023.05.010
- Taub AF, Pham K. "Stem Cells in Dermatology and Anti-aging Care of the Skin." Facial Plastic Surgery Clinics of North America. 2018;26(4):425–437. doi: 10.1016/j.fsc.2018.06.004
- Takahashi M, Umehara Y, Yue H, et al. "The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway." Frontiers in Immunology. 2021;12:712781. doi: 10.3389/fimmu.2021.712781
- Shimizu Y, Nakamura K, Kikuchi M, et al. "Lower human defensin 5 in elderly people compared to middle-aged." GeroScience. 2022;44(2):997–1009. PMID: 34105106
- Tetali B, Fahs FM, Mehregan D. "Popular over-the-counter cosmeceutical ingredients and their clinical efficacy." International Journal of Dermatology. 2019. doi: 10.1111/ijd.14718
- Grove GL, Kligman AM. "Age-associated changes in human epidermal cell renewal." Journal of Gerontology. 1983;38:137–142.
DefenAge® and Age-Repair Defensins® are registered trademarks of Progenitor Biologics LLC. References to retinol, tretinoin, and retinoid forms are for educational comparison purposes only. Product and ingredient names are the property of their respective owners. This content does not constitute medical advice and does not substitute for the advice of a licensed healthcare professional. Tretinoin and other prescription retinoids are regulated medications — consult your prescribing physician before making changes to any prescription regimen. These statements have not been evaluated by the Food and Drug Administration. DefenAge products are not intended to diagnose, treat, cure, or prevent any disease.